Validation of the production process of core-equipment HYNIC-Bombesin-Sn

The validation process is establishing documented evidence that provides a high degree of assurance that a specific process consistently will produce a product that will meet specifications and quality attributes preset and, therefore, ensures the efficiency and effectiveness of a product. The radiopharmaceutical 99mTc-HYNlC-Bombesin is part of the gastrin-releasing peptide (GRP) analogues of bombesin that are radiolabelled with technetium 99 metastable for molecular images obtention. Is obtained from freeze-dry formulations kits (core- equipment)) and has reported a very high stability in human serum, specific binding to receptors and rapid internalization. Biodistribution data in mice showed rapid blood clearance with predominant renal excretion and specific binding to tissues with positive response to GRP receptors. According to biokinetics studies performed on patients with breast cancer, breast show a marked asymmetry with increased uptake in neoplastic breast in healthy women and the uptake of radiopharmaceuticals is symmetrical in both breasts. No reported adverse reactions. In this paper, the prospective validation core-equipment HYNlC-Bombesin-Sn, which was shown consistently that the product meets the specifications and quality, attributes to preset from the obtained from the diagnostic radiopharmaceutical third generation: 99mTc-HYNlC-Bombesin. The process was successfully validated and thereby ensuring the efficiency and effectiveness of this agent as a preliminary diagnostic for approval to be marketed. (Author)